scholarly journals Self‐collection for HPV screening: a game changer in the elimination of cervical cancer

2021 ◽  
Author(s):  
Karen Canfell ◽  
Megan A Smith ◽  
Deborah J Bateson
Keyword(s):  
Cervical Cancer ◽  
Hpv Screening ◽  
Game Changer

Advances in HPV Screening Tests for Cervical Cancer—A Review

2021 ◽  
Author(s):  
Pesona Grace Lucksom ◽  
Mingma Lhamu Sherpa ◽  
Anup Pradhan ◽  
Sunaina Lal ◽  
Chamma Gupta
Keyword(s):  
Cervical Cancer ◽  
Screening Tests ◽  
Hpv Screening

Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland

2020 ◽  
Author(s):  
Olga Veijalainen ◽  
Saara Kares ◽  
Laura Kotaniemi‐Talonen ◽  
Paula Kujala ◽  
Risto Vuento ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Screening Program ◽  
Hpv Screening

scholarly journals Acceptability of human papillomavirus (HPV) self-sampling among never- and under-screened Indigenous and other minority women: a randomised three-arm community trial in Aotearoa New Zealand

2021 ◽  
Author(s):  
Naomi Brewer ◽  
Karen Bartholomew ◽  
Jane Grant ◽  
Anna Maxwell ◽  
Georgina McPherson ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
New Zealand ◽  
Cancer Screening ◽  
Usual Care ◽  
Cervical Cancer Screening ◽  
Trial Registration ◽  
Asian Women ◽  
Aotearoa New Zealand ◽  
Hpv Screening

AbstractBackgroundInternationally, self-sampling for human papillomavirus (HPV) has been shown to increase participation in cervical-cancer screening. In Aotearoa New Zealand, there are long-standing ethnic inequalities in cervical-cancer screening, incidence, and mortality; particularly for indigenous Māori women, as well as Pacific, and Asian women.MethodsWe invited never- and markedly under-screened (≥5 years overdue) 30-69-year-old Māori, Pacific, and Asian women to participate in an open-label, three-arm, community-based, randomised controlled trial, with a nested sub-study. We aimed to assess whether two specific invitation methods for self-sampling improved screening participation over usual care among the least medically served populations. Women were individually randomised 3:3:1 to: clinic-based self-sampling (CLINIC – invited to take a self-sample at their usual general practice); home-based self-sampling (HOME – mailed a kit and invited to take a self- sample at home); and usual care (USUAL – invited to attend a clinic for collection of a standard cytology sample). Neither participants nor research staff could be blinded to the intervention. In a subset of general practices, women who did not participate within three months of invitation were opportunistically invited to take a self-sample, either next time they attended a clinic or by mail.FindingsWe randomised 3,553 women: 1,574 to CLINIC, 1,467 to HOME, and 512 to USUAL. Participation was highest in HOME (14.6% among Māori, 8.8% among Pacific, and 18.5% among Asian) with CLINIC (7.0%, 5.3% and 6.9%, respectively) and USUAL (2.0%, 1.7% and 4.5%, respectively) being lower. In fully adjusted models, participation was statistically significantly more likely in HOME than USUAL: Māori OR=9.7, (95%CI 3.0-31.5); Pacific OR=6.0 (1.8-19.5); and Asian OR=5.1 (2.4-10.9). There were no adverse outcomes reported. After three months, 2,780 non-responding women were invited to participate in a non-randomised, opportunistic, follow-on substudy. After 6 months,192 (6.9%) additional women had taken a self-sample.InterpretationUsing recruitment methods that mimic usual practice, we provide critical evidence that self-sampling increases screening among the groups of women (never and under-screened) who experience the most barriers in Aotearoa New Zealand, although the absolute level of participation through this population approach was modest. Follow-up for most women was routine but a small proportion required intensive support.Trial registrationANZCTR Identifier: ACTRN12618000367246 (date registered 12/3/2018) https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371741&isReview=true;UTN:U1111-1189-0531FundingHealth Research Council of New Zealand (HRC 16/405)Protocolhttp://publichealth.massey.ac.nz/assets/Uploads/Study-protocol-V2.1Self-sampling-for-HPV-screening-a-community-trial.pdf

The impact of primary HPV screening on the incidence of cervical cancer in New Zealand

2019 ◽  
Vol 8 (5) ◽  
pp. 258-264 ◽  
Author(s):  
Brian Cox ◽  
Peter Fitzgerald ◽  
R. Marshall Austin ◽  
Mary Jane Sneyd
Keyword(s):  
Cervical Cancer ◽  
New Zealand ◽  
Hpv Screening ◽  
The Impact

Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region

2005 ◽  
Vol 43 (11) ◽  
Author(s):  
Brian J. Morris
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Genomic Dna ◽  
Advanced Disease ◽  
Pcr Primers ◽  
Nucleotide Variation ◽  
Viral Dna ◽  
Screening Strategies ◽  
Hpv Screening ◽  
Cervical Human Papillomavirus

AbstractPCR is a promising method for detection of human papillomavirus (HPV), the high-risk forms of which are responsible for cervical cancer. PCR primers that target the L1 or E1 region can be unreliable and may miss more advanced disease, whereas those directed at the E6 or E7 regions, which encode oncogenic products, are preferable because 1) the LI/E1 regions, but never the E6/E7 regions, are lost during integration of viral DNA into host genomic DNA, a process that can represent an integral component of progression from infection to tumorigenesis; and 2) the E6/E7 nucleotide sequence exhibits less nucleotide variation. The choice of region used for PCR has implications for HPV screening strategies in the clinical diagnosis and management of cervical cancer.

Sign in / Sign up

Export Citation Format

Share Document